Patents by Inventor Peter ULRICHTS

Peter ULRICHTS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240325528
    Abstract: Provided herein are unit dosage forms of a biologic that are determined based on a modeling approach, which matches a pharmacodynamic (PD) value of the SC dose with that of a known reference IV dose, while a pharmacokinetic (PK) value of the SC dose is less than that of the IV dose.
    Type: Application
    Filed: February 2, 2024
    Publication date: October 3, 2024
    Inventors: Antoinetta Jacoba Maria VAN BRAGT, Peter Ulrichts, Erik Hofman, Peter Verheesen
  • Publication number: 20230265201
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: July 11, 2022
    Publication date: August 24, 2023
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • Patent number: 11505585
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 22, 2022
    Assignees: argenx BV, The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Patent number: 11434298
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: September 6, 2022
    Assignee: ARGENX BV
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Publication number: 20220275035
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 1, 2022
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Patent number: 11072665
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 27, 2021
    Assignee: argenx BVBA
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Publication number: 20200024344
    Abstract: A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists.
    Type: Application
    Filed: June 7, 2019
    Publication date: January 23, 2020
    Inventors: Hans de Haard, Peter Ulrichts, Thierry Cousin, Nicolas Leupin, Torsten Dreier, Tonke Van Bragt
  • Publication number: 20190270823
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 18, 2019
    Publication date: September 5, 2019
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Publication number: 20190194277
    Abstract: Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.
    Type: Application
    Filed: December 7, 2018
    Publication date: June 27, 2019
    Inventors: Johannes de Haard, Torsten Dreier, Peter Ulrichts, Antonio Guglietta, Nicolas Leupin
  • Patent number: 10316073
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 11, 2019
    Assignees: argenx BVBA, The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Publication number: 20180179258
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 28, 2018
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Patent number: 9926364
    Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: March 27, 2018
    Assignee: ARGEN-X N.V.
    Inventors: Johannes Joseph Wilhelmus De Haard, Natalie De Jonge, Anna Hultberg, Christophe Blanchetot, Karen Silence, Peter Ulrichts, Torsten Dreier
  • Publication number: 20170369581
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 19, 2015
    Publication date: December 28, 2017
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • Patent number: 9765148
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: September 19, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Patent number: 9765149
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: September 19, 2017
    Assignee: ARGEN-X N.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Publication number: 20160264669
    Abstract: Provided are novel methods of reducing the serum levels of Fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn-antagonist that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. The disclosed methods are particularly useful for treating antibody-mediated disorders (e.g. autoimmune diseases).
    Type: Application
    Filed: March 8, 2016
    Publication date: September 15, 2016
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, Nicolas G.H. Ongenae
  • Publication number: 20160207996
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof derived from antibodies raised by DNA immunization of host animals, particularly camelids (e.g. llama). The antibodies and antigen binding fragments thereof bind to proteins which may be particularly large in size (at least 1115 amino acids in length), or have at least 8 transmembrane domains, or are naturally encoded by nucleotide sequences which are difficult to replicate in standard or common E. coli strains. The present invention also relates to antibodies and antigen binding fragments thereof which bind to ion channels, in particular the voltage-gated sodium channel Nav1.7. Methods of raising antibodies against particular protein targets by a process of DNA immunization are also provided.
    Type: Application
    Filed: September 5, 2014
    Publication date: July 21, 2016
    Inventors: Peter Ulrichts, Sebastian Van Der Woning, Gitte De Boeck, Erik Hofman, Christophe Blanchetot, Michael Saunders, Johannes Joseph Wilhelmus De Haard
  • Publication number: 20150266963
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 19, 2015
    Publication date: September 24, 2015
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • Publication number: 20150218239
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Application
    Filed: December 23, 2014
    Publication date: August 6, 2015
    Applicants: arGEN-X B.V., The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Publication number: 20140286976
    Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.
    Type: Application
    Filed: November 5, 2012
    Publication date: September 25, 2014
    Applicant: arGEN-X B.V.
    Inventors: Johannes Joseph Wilhelmus De Haard, Natalie De Jonge, Anna Hultberg, Christophe Blanchetot, Karen Silence, Peter Ulrichts, Torsten Dreier